Sino Biopharmaceutical (HKG:1177) presented the latest results of the phase III clinical study for benmelstobart injection in combination with anlotinib hydrochloride capsules at the American Society of Clinical Oncology's annual meeting
The drug is being tested as first-line treatment for non-small cell lung cancer in comparison with the pembrolizumab injection.
The study has achieved the primary study endpoint of progression-free survival, in which the median survival was prolonged by more than 6 months in the population with TPS ≥50%.
There was also a 40% reduction in the risk of disease progression and death as compared with the arm of pembrolizumab.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.